Answers are grounded in this paper and cite their sources.
Viral bronchiolitis continues to be a major public health problem. Prevention of severe RSV-associated bronchiolitis has been achieved in high-risk infants by passive administration of the humanized monoclonal anti-RSV-F antibody, palivizumab. Development of more potent anti-RSV neutralizing antibodies is underway, and vaccine development continues to progress. Supportive therapy is the mainstay for the treatment of established infection while new antiviral and anti-inflammatory strategies are being explored in preclinical trials.
No takes yet. Share an insight, caveat, or question.
Domachowske et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: